# GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT00776802** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **La Jolla Pharmaceutical Company**

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** GCS-100
- **DRUG:** Etoposide; Dexamethasone

## Key facts

- **NCT ID:** NCT00776802
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-07
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2013-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776802, "GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00776802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*